Revolution Medicines delivered a pivotal Q1 2026, highlighted by transformative RASolute 302 results for daraxonrasib in metastatic pancreatic cancer, driving a 60% reduction in risk of death versus ...
APD Air Products and Chemicals, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results